SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Shaanxi Micot Reports Positive Phase II Stroke Trial Results

The company said MT200605’s high-dose arm met the primary endpoint and key secondary endpoints in a Phase II acute ischemic stroke trial, with favorable safety. It signaled plans for Phase III trials and potential partnerships outside China.

2335

Related stories